AN2 Therapeutics (ANTX) Cash from Financing Activities (2021 - 2026)
AN2 Therapeutics (ANTX) reported Cash from Financing Activities of $37.3 million for Q1 2026, up 57329.23% year-over-year from N/an in Q1 2025, and up 77668.75% quarter-over-quarter from $48000.0 in Q3 2025.
AN2 Therapeutics (ANTX) Cash from Financing Activities (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Cash from Financing Activities data on file, last reported at $37.3 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $37.3 million, up 57329.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.4 million (up 42373.86% YoY), and the FY2025 annual result was $113000.0, down 69.62% from the prior year.
- Cash from Financing Activities grew to $37.3 million in Q1 2026 per ANTX's latest filing, from $48000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $66.1 million in Q3 2023 and troughed at -$321000.0 in Q4 2023.
- A 5-year average of $16.1 million and a median of $274000.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 660760.0% in 2023, then sank 99.97% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at -$10000.0 in 2022, then sank by 3110.0% to -$321000.0 in 2023, then jumped by 107.17% to $23000.0 in 2024, then surged by 108.7% to $48000.0 in 2025, then jumped by 77668.75% to $37.3 million in 2026.
- Business Quant data shows ANTX's Cash from Financing Activities at $37.3 million in Q1 2026, $48000.0 in Q3 2025, and $65000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 85,464.43 |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | 37.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.33 Mn |
| Mar 31, 2026 | 37.33 Mn |
| Sep 30, 2025 | 48,000.00 |
| Sep 30, 2025 | 48,000.00 |
| Mar 31, 2025 | 65,000.00 |
| Mar 31, 2025 | 65,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Mar 31, 2024 | 349,000.00 |
| Mar 31, 2024 | 349,000.00 |
| Dec 31, 2023 | -321,000.00 |
| Dec 31, 2023 | -321,000.00 |
| Sep 30, 2023 | 66.07 Mn |
| Sep 30, 2023 | 66.07 Mn |
| Jun 30, 2023 | 19.05 Mn |
| Jun 30, 2023 | 19.05 Mn |
| Mar 31, 2023 | 199,000.00 |
| Mar 31, 2023 | 199,000.00 |
| Sep 30, 2022 | -10,000.00 |
| Sep 30, 2022 | -10,000.00 |